{
    "clinical_study": {
        "@rank": "67106", 
        "arm_group": {
            "arm_group_label": "Full Analysis Set", 
            "description": "Full Analysis Set (FAS): The FAS contains any patient that has given written informed consent."
        }, 
        "brief_summary": {
            "textblock": "This is a prospective non-interventional observational study to evaluate the treatment of\n      moderately active RA patients in every day clinical practice in Austria. Patients will be\n      observed over 52 weeks. The primary endpoint will be percentage of patients who reach CDAI\n      remission after 24 weeks."
        }, 
        "brief_title": "Study to Observe the Safety and Efficacy of Etanercept (Enbrel\u00ae) in Patients With Moderately Active Rheumatoid Arthritis in Every Day Clinical Practice in Austria", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "detailed_description": {
            "textblock": "Non-interventional observational study, national, multicenter prospective non-interventional\n      study (NIS) as defined by the Austrian Drug Law \u00a7 2a Section 3 N/A"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. The patient is eligible to receive Etanercept treatment according to the Austrian\n             SmPC.\n\n          2. The decision to treat the patient with Etanercept has been made independently by the\n             physician and is clearly separated from the decision to include the patient in the\n             study. The treatment decision was made in advance and is not dependent on the\n             protocol.\n\n          3. The patient was informed about the study and gave his/her consent and signed an\n             Independent Ethics Committee (IEC) submitted written Informed Consent form on use of\n             the data.\n\n          4. The patient has moderately active RA, defined as a disease activity of CDAI >10 and\n             \u226422 and/or DAS28 (CRP)>3.2 and \u2264 5.1\n\n        Exclusion Criteria:\n\n          1. Any contraindication according to the Austrian SmPC, which includes:\n\n             A hypersensitivity to any component of Etanercept, active tuberculosis or any other\n             serious infection.\n\n          2. Patient has previously participated in this study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with moderately active RA that are treated with Etanercept will be studied. All\n        patients enrolled should meet the usual prescribing criteria for Etanercept as per the\n        Austrian SmPC and should be entered into the study at the investigator's discretion."
            }
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01877239", 
            "org_study_id": "B1801357"
        }, 
        "intervention": {
            "arm_group_label": "Full Analysis Set", 
            "description": "observation of Etanercept treatment in moderately active RA patients in Austria. Etanercept treatment according to Austrian SmPC", 
            "intervention_name": "non-intervention", 
            "intervention_type": "Other"
        }, 
        "intervention_browse": {
            "mesh_term": "TNFR-Fc fusion protein"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 14, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1801357&StudyName=Study%20to%20Observe%20the%20Safety%20and%20Efficacy%20of%20Etanercept%20%28enbrel%AE%29%20in%20Patients%20with%20Moderately%20Active%20Rheumatoid%20Arthritis%20in%20Every%20"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Graz", 
                        "country": "Austria", 
                        "zip": "8010"
                    }, 
                    "name": "Ordination Dr. Thomas Muller"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Graz", 
                        "country": "Austria", 
                        "zip": "8020"
                    }, 
                    "name": "Barmherzige Br\u00fcder Graz Eggenberg"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Graz", 
                        "country": "Austria", 
                        "zip": "8020"
                    }, 
                    "name": "Ordination Dr. Franz Rainer"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Linz", 
                        "country": "Austria", 
                        "zip": "4030"
                    }, 
                    "name": "Ordination Dr. Wilhelm Kaiser"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Linz", 
                        "country": "Austria", 
                        "zip": "4020"
                    }, 
                    "name": "Ordination Dr. Richard Janetschko"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Linz", 
                        "country": "Austria", 
                        "zip": "4040"
                    }, 
                    "name": "Dr. Eichbauer-Sturm"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wien", 
                        "country": "Austria", 
                        "zip": "1130"
                    }, 
                    "name": "Ordination Dr. Peter Peichl"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wien", 
                        "country": "Austria", 
                        "zip": "1170"
                    }, 
                    "name": "Ordination Dr. Maya Thun"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wiener Neudorf", 
                        "country": "Austria", 
                        "zip": "2351"
                    }, 
                    "name": "Ordination Dr. Thomas Schwingenschlogl"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Austria"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Multicenter Non-interventional Study to Observe the Safety and Efficacy of Etanercept (Enbrel\u00ae) in Patients With Moderately Active Rheumatoid Arthritis in Every Day Clinical Practice in Austria", 
        "overall_contact": {
            "last_name": "Pfizer CT.gov Call Center", 
            "phone": "1-800-718-1021"
        }, 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Austria: Agency for Health and Food Safety", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Descriptive statistics on percentage of patients achieving remission, (CDAI\u22642.8 at approximately Week 24). Eligible Set - primary population to be used for efficacy analysis: all patients that have evaluable CDAI assessments at Baseline and Week 24", 
            "measure": "Percentage of Participants achieving CDAI Remission", 
            "safety_issue": "No", 
            "time_frame": "24 Weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01877239"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "CDAI status of disease activity (\u22642.8 - remission, \u226410 - low disease activity, \u226422 - moderate disease activity, or >22 - high disease activity) at approximately Week 12 (Visit 3), Week 52 (Visit 5) - Percentage of Patients in Remission, Low Disease Activity, Moderated- or High Disease Activity", 
                "measure": "CDAI status of disease activity at approximately Week 12, Week 52", 
                "safety_issue": "No", 
                "time_frame": "up to 52 weeks"
            }, 
            {
                "description": "Change from Baseline to approximately Week 12 (Visit 3), Week 24 (Visit 4) and Week 52 (Visit 5) in CDAI - descriptive statistics of mean change", 
                "measure": "Change from Baseline to Week 12, Week 24  and Week 52 in CDAI", 
                "safety_issue": "No", 
                "time_frame": "up to 52 weeks"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}